A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
1,840actual
Sites
447
Countries
Argentina, Australia, Austria +34
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-05-18 | actual | When the study began enrolling |
| Primary completion | 2025-09-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-30 | actual | The whole study's end, after follow-up |
| First posted | 2021-03-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Early Alzheimer's Disease
Interventions
- Drug: Semagludtide
- Drug: Placebo (semaglutide)
Primary outcome
what the primary-completion date above is the date OFChange in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) score
measured From baseline (week 0) to week 104
Publications
- PMID 41865758 — linked by the registry
- PMID 39780249 — linked by the registry
- PMID 38901446 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed